E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Intradural anaesthesia |
Anestesia intradural |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10002091 |
E.1.2 | Term | Anaesthesia |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective is to assess the effect of bupivacaine or levobupivacaine on peroperatory regional cerebral oximetry during anaesthesia in elderly patients undergoing hip replacement surgery |
El objetivo principal será evaluar el efecto sobre la oximetría regional cerebral peroperatoria (SrO2) de la utilización de bupivacaína o de levobupivacaína en la anestesia intradural en el paciente anciano sometido a cirugía ortopédica mayor por fractura de fémur |
|
E.2.2 | Secondary objectives of the trial |
Compare between patients treated with bupivacaine or levobupivacaine the following parameters: 1. Change in cognitive function after surgery 2. Hemodynamic changes induced by anaesthetic blockade and administration of vasoconstrictor drugs during anaesthesia 3. Characteristics of sensorial and motor blockade induced by intradural anaesthesia 4. Degree of intrasurgical bleeding 5. Changes in renal function 6. Clinical complications during hospitalization 7. Mortality after 30 days |
Comparar: 1. La modificación de la función cognitiva respecto de los valores preoperatorios. 2. Los cambios hemodinámicos inducidos por bloqueo anestésico y la administración de fármacos vasoconstrictores durante la anestesia. 3. Las características de los bloqueos sensorial y motor producidos por la anestesia intradural. 4. El grado de sangrado intraoperatorio 5. Los cambios en la función renal respecto de los valores del preoperatorio. 6. Las complicaciones clínicas hasta el alta hospitalaria 7. Mortalidad a treinta días |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients older than 70 years old who undergo major orthopaedic surgery for hip replacement and will receive intradural anaesthesia 2. Patients who give their informed consent to participate in the study |
1. Pacientes ancianos mayores de 70 años que van a ser sometidos a cirugía ortopédica mayor por fractura de fémur tributarios de anestesia intradural. 2. Que hayan otorgado su consentimiento informado a participar en el estudio |
|
E.4 | Principal exclusion criteria |
1. Patients allergic to anaesthetic drugs to be used in the protocol 2. Patients with severe aortic estenosis 3. Patients who refuse the anaesthetic technique 4. Patients with severe cognitive impairment previous to the intervention (defined by a score in the Pfeiffer test of 8-10 errors) 5. Any condition that, in the investigator's opinion, could pose a risk to the patient |
11. Pacientes alérgicos a los anestésicos locales empleados 2. Pacientes con estenosis aórtica severa. 3. Rechazo de la técnica anestésica por parte del paciente. 4. Puntuación test de Pfeiffer previa a la intervención quirúrgica: 8-10 errores (deterioro cognitivo severo) 5. Pacientes en los que se considere que la participación en el estudio puede suponer un perjuicio clínico, en opinión del médico responsable del cuidado del paciente. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of intraoperative time with a decrease or cerebral regional saturation (SrO2), of at least 20% with respect to baseline values |
La variable principal del estudio será el porcentaje de tiempo intraoperatorio en el que se detecta un descenso de la saturación regional cerebral O2 (SrO2) del 20% con respecto a los valores basales |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
During the surgery |
Dirante la cirugí |
|
E.5.2 | Secondary end point(s) |
? Change in cognitive function after 5 or 7 days with respect to preoperative function, measured by means of the Pfeiffer cognitive test |
? La modificación de la función cognitiva al cabo de 5 a 7 días de la intervención quirúrgica respecto de los valores preoperatorios, valorada mediante el número de errores en el test cognitivo de Pfeiffer (SPMSQ). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Measured at day 5 or 7 post-surgery |
Valorado al dia 5 ó 7 post cirugía |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |